ETElisa Turriani

Elisa Turriani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elisa Turriani has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence of respiratory syncytial virus and influenza: A Danish nationwide cohort study

    by Maria João Fonseca, Stanislava Bratković, Mikkel Pedersen, Mathilde Kany, Triantafyllos Pliakas, Rachel Reeves, Alen Marijam, Elisa Turriani, Nikoline Vestergaard Dich, Yunus Çolak, et al.

    Respiratory syncytial virus (RSV) is, like influenza, one of the most common causes of severe acute respiratory infections (ARIs) in adults; however, its incidence across different risk and age groups is unknown. We estimated the incidence of registered ARIs in Danish adults, focusing on RSV and contextualizing with influenza. We conducted a nationwide cohort study in Denmark, including all adults aged ≥18 y with a registered ARI, during the 2011/12 to 2022/23 seasons. We estimated the incidence (per 100,000 person-years) of ARI overall and ARI attributable to RSV or influenza, overall and stratified by sex, age, and comorbidity. We identified 962,858 ARIs, of which 10,437 (1.1%) were attributed to RSV and 62,869 (6.5%) to influenza. The ARI incidence increased over time (range: 1,272-2,144), including a rise in RSV incidence (range: 0.2-91.6), while influenza incidence fluctuated (range: 6.7-322.0). In the 2022/23 season, RSV incidence was higher among females, older adults (198.7 in ≥60-y-olds, and 303.2 in ≥75-y-olds), and those with comorbidities, especially hematologic disease (868.6) and chronic obstructive pulmonary disease (679.5). Although influenza incidence was generally higher than RSV, the incidences were comparable for older adults and those with comorbidities. In conclusion, RSV is an important cause of ARIs among adults, comparable to influenza, particularly in older adults and those with comorbidities. These findings underscore the substantial burden of RSV that is relevant for public health planning and clinical decision-making, particularly given the recent approval of three highly effective RSV vaccines.


  • Open Access

    Reply to letter to editor “public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany”

    by Maria Waize, Pavo Marijic, Alen Marijam, Foteini Gkalapi, Elisa Turriani, Franziska Jakobs, Indra Jaidhauser, Dorothea Münch, Sara Pedron, Eleftherios Zarkadoulas

  • Open Access

    Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany

    by Maria Waize, Pavo Marijic, Alen Marijam, Foteini Gkalapi, Elisa Turriani, Franziska Jakobs, Indra Jaidhauser, Dorothea Münch, Sara Pedron, Eleftherios Zarkadoulas

    Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in older adults. Vaccination is effective against RSV disease and can reduce disease and economic burden. A static, multicohort Markov model was adapted to the German setting to estimate the public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination strategies from a societal perspective in three target populations: 1) at increased risk (AIR) adults aged 50-59 years and all adults ≥60 years, 2) all adults aged ≥60 years, and 3) AIR adults aged 60-74 years and all adults ≥75 years. A cycle length of 1 month and a 5-year time horizon were adopted. Vaccine coverage was 75% in the base case. RSV vaccination is cost-effective versus no vaccination (<€50,000 willingness-to-pay threshold): incremental cost-effectiveness ratios were €19,789, €19,631, and €12,733 for strategies 1, 2 and 3, respectively; 1.6, 1.4, and 0.8 million outpatient visits and 192,402, 185,238, and 152,781 hospitalizations could be prevented with strategies 1, 2, and 3, respectively. Expanding RSV vaccination to a larger target population would prevent more RSV cases, though at a higher cost per case averted; all vaccination strategies would be deemed cost-effective in Germany.


  • Open Access

    Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries

    by Marina George, Jaime Pérez Martin, Mohammad AbdelGhany, Foteini Gkalapi, Nicolas Jamet, Richelle C. Kosse, Yara Ruiz García, Elisa Turriani, Valérie Berlaimont

    The hexavalent vaccines DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib are routinely used for primary immunization of infants against diphtheria, tetanus, pertussis, hepatitis B virus, poliomyelitis, and Haemophilus influenzae type b. A recent publication showed that after primary immunization with these vaccines, the odds ratios of adverse reactions (ARs) were significantly lower for DT3aP-HBV-IPV/Hib than for DT2aP-HBV-IPV-Hib. Our aim is to understand the impact of the various reactogenicity profiles at country level by comparing the ARs induced by one dose of DT3aP-HBV-IPV/Hib versus DT2aP-HBV-IPV-Hib in the primary infant immunization course. A mathematical projection tool was developed to simulate vaccination of infants with both vaccines in six countries: Austria, the Czech Republic, France, Jordan, Spain, and the Netherlands. Proportions of three local and five systemic ARs of interest for both vaccines were based on findings from a previous meta-analysis of ARs in infants. The absolute risk reductions calculated ranged from 3.0% (95% confidence interval [CI]: 2.8%–3.2%) for “Swelling at the injection site, any grade” to 10.0% (95% CI: 9.5%–10.5%) for “Fever, any grade.” The difference in occurrence of the AR “Fever, any grade” between vaccines in 2020 ranged from over 7,000 in Austria to over 62,000 in France. Over 5 years, this would amount to a reduction of over 150,000 ARs in Austria and over 1.4 million ARs in France when using DT3aP-HBV-IPV/Hib instead of DT2aP-HBV-IPV-Hib. In conclusion, the estimated numbers of ARs following hexavalent vaccination in six countries showed that vaccination of infants with DT3aP-HBV-IPV/Hib could lead to fewer ARs than vaccination with DT2aP-HBV-IPV-Hib. Vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b is often performed with combined vaccines against these six diseases. In many countries, these are the first vaccinations received by infants, and potential adverse reactions could affect compliance with future vaccinations. A previous study examined two of the combined vaccines, DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib, and showed that local adverse reactions at the injection site (pain, redness, and swelling) and general adverse reactions (fever, drowsiness, irritability, persistent crying, and lack of appetite) were less common after vaccination with DT3aP-HBV-IPV/Hib than with DT2aP-HBV-IPV-Hib. To understand the impact of this finding at a population level, we compared the adverse reactions caused by the hypothetical administration of the two vaccines under similar conditions. We simulated the vaccination of infants with both vaccines in six countries: Austria, the Czech Republic, France, Jordan, Spain, and the Netherlands. The simulation showed that the DT3aP-HBV-IPV/Hib vaccine could reduce cases of swelling at the injection site by 3% and fever by 10%. For the year 2020, the resulting reduction in the estimated number of fever occurrences would have ranged from over 7,000 in Austria to over 62,000 in France. In total, adverse reactions avoided could hypothetically have ranged from 30,781 in Austria to 269,025 in France. Over 5 years, this could have avoided an estimated number of adverse reactions of over 150,000 in Austria to over 1.4 million in France. In conclusion, such a switch of vaccine could substantially reduce adverse reactions.


  • Open Access

    Hexavalent vaccines: What can we learn from head-to-head studies?

    by Markus Knuf, Hervé Haas, Pilar Garcia-Corbeira, Elisa Turriani, Piyali Mukherjee, Winnie Janssens, Valérie Berlaimont


  • Open Access

    Diphtheria-tetanus-pertussis (DTP) vaccination: understanding the perspectives and expectations of parents and healthcare professionals in France and India

    by Pierre Bakhache, Vijay Yewale, Raunak Parikh, Gabriella Clancey, Gemma Spickernell, Valérie Berlaimont, Elisa Turriani

    Diphtheria-tetanus-pertussis (DTP) combination vaccines are a cornerstone of infant vaccinations worldwide. DTP vaccine acceptance could be impacted by sub-optimal relationships between parents and healthcare professionals (HCPs). This survey, conducted in France and India between 14/2/2020 and 26/3/2020, aimed to understand perspectives and expectations of parents and HCPs toward DTP vaccination. Participants were parents (parents/guardians of ≤3-year-old children; France: n = 1002, India: n = 1021) and HCPs (general practitioners/pediatricians initiating DTP vaccination; France: n = 300; India: n = 300) who chose to take part. A representative sample of parents was achieved via quotas and random iterative weighting to match key demographics of the target population. In India, only parents from socio-economic classes A/B/C and private HCPs were included. Whilst DTP vaccine acceptance was high among parents in France (85%) and India (98%), French HCPs overestimated parental acceptance (99% thought parents were very/fairly accepting). The proportions of parents reporting that the HCP is someone they trust versus the proportions of HCPs wanting to be seen as trusted were discrepant in France (76% versus 90%) but not India (83% versus 85%). Some surveyed parents indicated that, ideally, they would like some input in vaccine brand decisions alongside HCPs, an opinion shared by some HCPs. In France, short-term experience post-vaccination was more important to parents than HCPs, for whom long-term protection was more important. In India, these aspects were equally important to both. Increased awareness of parents’ priorities and concerns regarding DTP vaccination can support HCPs in their discussions with parents and help build trust, which may impact vaccine acceptance. Graphical abstract


  • Open Access

    Seroprevalence of Bordetella pertussis Infection in Patients With Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort

    by Tom M. A. Wilkinson, Peter Van Den Steen, Brigitte Cheuvart, Nathalie Baudson, Monique Dodet, Elisa Turriani, Lauriane Harrington, Nadia Meyer, Simona Rondini, Laura Taddei, et al.

    Pertussis is underdiagnosed and underreported in adults and patients with underlying conditions. Patients with chronic obstructive pulmonary disease (COPD) may be at increased risk of severe pertussis. Understanding the true prevalence of pertussis infections in such patients is important. We therefore evaluated the seroprevalence of anti-pertussis toxin (PT) antibodies in a cohort of 40–85-year-old patients diagnosed with moderate, severe or very severe COPD enrolled (between June 2011 and June 2012) in the prospective, observational “Acute Exacerbation and Respiratory InfectionS in COPD” (AERIS; NCT01360398) study, conducted in England. Serum anti-PT antibodies were measured in 104 patients using an enzyme-linked immunosorbent assay on samples collected 12 months (M12) and 24 months (M24) after enrollment. Overall, 14/104 (13.5%) patients had anti-PT concentrations ≥50 IU/mL at M12 or M24, indicative of exposure to Bordetella pertussis during the preceding 2–3 years. Of these, 6/104 (5.8%) had anti-PT ≥70 IU/mL, of whom 3/104 (2.9%) had anti-PT ≥120 IU/mL, indicative of exposure within 12 and 6 months, respectively. These results show a high circulation of B. pertussis in 40–85-year-old patients with moderate, severe or very severe COPD in England between 2012 and 2014, and call for enhanced immunization to prevent pertussis infections in such patients.


  • Open Access

    Perceptions of vaccine preventable diseases in Australian healthcare: focus on pertussis

    by Julianne Bayliss, Roshnee Randhawa, Kyu-Bin Oh, Walid Kandeil, Victoria A. Jenkins, Elisa Turriani, Michael Nissen

    Adult vaccination in Australia is suboptimal. For instance, as few as one in nine people have received a pertussis vaccine in adolescence or adulthood, despite increasing disease burden and evidence of a positive correlation between older age and hospitalization rates. The objectives of this study were to describe general practitioners’ (GPs) and adult consumers’ knowledge and attitudes toward adult vaccination, with an emphasis on pertussis. Australian GPs and consumers were recruited in two nationally representative online surveys repeated annually between 2014 and 2018. Vaccination discussions occurred in a minority of adult/GP encounters. Pertussis was among the five most frequently identified vaccine preventable diseases but was unlikely to be proactively discussed with adults not in contact with young children. Among consumers, only one in three recalled ever receiving a pertussis vaccination. GPs are a strong predictor of adults receiving a pertussis vaccine. Possible factors contributing to low uptake are misconceptions around pertussis disease, vaccination requirements and lack of GP recommendation for adult vaccination. GPs have a key role to play in increasing adult vaccination coverage with their recommendation.


  • Open Access

    Evaluation of two frailty indices, with practical application in a vaccine clinical trial

    by Desmond Curran, Melissa K. Andrew, Myron J. Levin, Elisa Turriani, Sean Matthews, Charles Fogarty, Nicola P. Klein, Katrijn Grupping, Lidia Oostvogels, Kenneth E. Schmader

    Frail older adults are at increased risk of poor clinical outcomes. Frailty assessment is therefore important in clinical trials to understand the benefits and harms of interventions. However, consensus is lacking on how frailty should be assessed. We developed a prospectively specified index using a battery of formal tests and instruments and a retrospectively generated index using medical comorbidities and patient reported outcomes (PROs) within an adjuvanted recombinant zoster vaccine (RZV) trial (NCT02979639). For both frailty indices (FIs), a total deficit score was calculated as the accumulation of deficits and participants were categorized as non-frail, pre-frail and frail. We assessed (1) the feasibility and validity of both FIs; (2) the impact of RZV vaccine reactogenicity by frailty status on Short Form-36 [SF-36] physical functioning (PF) scores. Of 401 participants, aged ≥50 years, 236 (58.9%) were categorized non-frail, 143 (35.7%), pre-frail, and 22 (5.5%) frail using the prospective FI. Corresponding numbers for the retrospective FI were 192 (47.9%), 169 (42.1%) and 40 (10.0%), respectively. Strong concordance was observed between the frailty status assessments (P < .001). The proportion defined as frail increased from 1.5%, to 10.4% in participants aged 50–59, and ≥70 years, respectively, for the prospective FI. Corresponding numbers for the retrospective FI were 3.7%, and 17.2%, respectively. RZV vaccination was associated with a transient, non-clinically meaningful, decrease on the SF-36 PF score in frail participants. Both frailty indices provided similar results. The retrospectively generated FI offers the advantage of being easier to incorporate into vaccine clinical trials of older adults.